The company’s partner Leosons International has received approval for Kerasal Nail in UAE.

According to Moberg Pharma, launch preparations of the product will start immediately. In October 2013 a distribution agreement was signed sixteen markets in the MENA region (Middle East and North Africa). “We signed the distribution agreement with Leosons just three months ago. The rapid approval confirms our strong belief that Leosons will do a great job distributing Kerasal Nail across the MENA region. The region includes more than 200 million people and represents a growing market opportunity. UAE is an important market and the expeditious approval of Kerasal Nail™ provides support for registrations in other countries in the region,” said Peter Wolpert, President and CEO of Moberg Pharma AB.